Disease-A-Month
Volume 52, Issue 11 , Pages 420-427 , November 2006

Tuberculosis and HIV Infection

References 

  1. Reider HL, Cauthen GM, Kelly GD, Bloch AB, Snider DE. Tuberculosis in the United States. JAMA. 1989;262:385–389
  2. CDC Trends in TB in the United States 1998-2003. MMWR. 2004;53:209–214
  3. http://www.who.int/tb/hiv/faw/en/index.html
  4. Barnes PF, Bloch AB, Davidson PT, et al. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med. 1992;324:1644–1650
  5. http://www.who.int/mediacentre/factsheets/fs104/en/index.html
  6. Nunn P, Williams B, Floyd K, et al. Science and society: tuberculosis control in the era of HIV. Nat Rev Immunol. 2005;5:819–826
  7. Khan K, Muennig P, Behta M, et al. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med. 2004;350:2060–2067
  8. Pitchenik AE, Fertel D, Bloch AB. Mycobacterial disease: epidemiology, diagnosis, treatment, and prevention. Clin Chest Med. 1988;9:425–441
  9. Hass DW, Des Prez RM. Tuberculosis and acquired immunodeficiency syndrome: a historical perspective on recent developments. Am J Med. 1994;96:439–450
  10. Slutsker L, Castro KG, Ward JW, et al. Epidemiology of extrapulmonary tuberculosis among persons with AIDS in the United States. Clin Infect Dis. 1993;16:513–518
  11. Gordin FM, Nelson ET, Matts JP, et al. The impact of human immunodeficiency virus infection on drug-resistant tuberculosis. Am J Respir Crit Care Med. 1996;154:1478–1483
  12. Beck-Sague C, Dooley SW, Hutton MD, et al. Hospital outbreak of multi-drug resistant mycobacterium tuberculosis infections: factors in transmission to staff and HIV-infected patients. JAMA. 1992;268:280–286
  13. Centers for Disease Control. Mycobacterium tuberculosis transmission in a health clinic; Florida. MMWR Morb Mortal Wkly Rep. 1989;38:256
  14. Moreno S, Miralles P, Diaz MD, et al. Isoniazid preventive therapy in human immunodeficiency virus infected persons: long-term effect on development of tuberculosis and survival. Arch Intern Med. 1997;15:1729–1734
  15. Whalen C, Horsburg CR, Hom D, et al. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med. 1995;15:129–135
  16. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320:545–550
  17. Toossi Z, Mayanja-Kizza H, Hirsch CS, et al. Impact of tuberculosis on HIV-1 activity in dually infected patients. Clin Exp Immunol. 2001;123:233–238
  18. Dufour V, Cadranel J, Wislez M, et al. Changes in the pattern of respiratory diseases necessitating hospitalization of HIV infected patients since the advent of highly active antiretroviral therapy. Lung. 2004;182:331–341
  19. Chaisson RE, Schecter GF, Theuer CP, et al. Tuberculosis in patients with the acquired immunodeficiency syndrome (Clinical features, response to therapy, and survival). Am Rev Respir Dis. 1987;136:570–574
  20. Hirsch HH, Kaufmann G, Sendi P, et al. Immune reconstitution in HIV-infected patients. Clin Infect Dis. 2004;38:1159–1166
  21. Michaildis C, Pozniak AL, Mandalia S, et al. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther. 2005;10:417–422
  22. Navas E, Martin-Davila P, Moreno L, et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Int Med. 2002;162:97–99
  23. Breen RA, Smith CJ, Bettinson H, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax. 2004;59:704–707
  24. CDC/USPHS/IDSA. Guidelines for the treatment of opportunistic infections among HIV-infected adults and adolescents. MMWR. 2004;53:1–112
  25. Dean GL, Edwards SG, Iveg NJ, et al. Treatment of tuberculosis in HIV infected persons in the era of highly active antiretroviral therapy. AIDS. 2002;16:75–83
  26. Small PM, Schecter GF, Goodman PC, et al. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med. 1991;324:289–294
  27. Markowitz N, Hansen NI, Wilcosky TC, et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Intern Med. 1993;119:185–193
  28. Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med. 1998;158:157–161
  29. Finch D, Beaty CD. The utility of a single sputum specimen in the diagnosis of tuberculosis: comparison between HIV infected and non HIV infected patients. Chest. 1997;111:1174–1179
  30. Smith RL, Yew K, Berkowitz KA, et al. Factors affecting the yield of acid-fast sputum smears in patients with HIV and tuberculosis. Chest. 1994;106:684–686
  31. Chakravorty S, Sen MK, Tyagi JS. Diagnosis of extrapulmonary tuberculosis by smear, culture and PCR using universal sample processing technology. J Clin Microbiol. 2005;43:4357–4362
  32. Piersimoni C, Scarparo C, Callegaro A, et al. Comparison of MB/Bact alert 3D system with radiometric BACTEC system and Lowenstein-Jensen medium for recovery and identification of mycobacteria from clinical specimens: a multicenter study. J Clin Microbiol. 2001;39:651–657
  33. ATS/CDC/IDSA. Treatment of tuberculosis. MMWR. 2003;52(RR-11):1–77
  34. CDC. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR. 2000;49:185–200

PII: S0011-5029(06)00089-7

doi: 10.1016/j.disamonth.2006.09.006

Disease-A-Month
Volume 52, Issue 11 , Pages 420-427 , November 2006

Article Tools